Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Thomas J. Kipps, Graeme Fraser, Steven E. Coutre, Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, John C. Byrd, Susan M. O'Brien, Marie Sarah Dilhuydy, Peter Hillmen, Ulrich Jaeger, Carol Moreno, Paula Cramer, Stephan Stilgenbauer, Asher A. Chanan-Khan, Michelle Mahler, Mariya Salman, Karl Eckert, Isabelle G. Solman, Sriram BalasubramanianMei Cheng, Anil Londhe, Joi Ninomoto, Angela Howes, Danelle F. James, Michael Hallek

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A pooled analysis of 1238 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from three phase 3 studies found that genomic risk factors were not associated with shorter progression-free survival (PFS) or overall survival for patients treated with ibrutinib. Ibrutinib-treated patients with del(11q) were found to have a longer PFS than those without del(11q). These results suggest less prognostic relevance for certain genomic risk factors with ibrutinib treatment.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Outcome Assessment (Health Care)
Disease-Free Survival
Therapeutics
Survival
PCI 32765

Keywords

  • Prognostic factors
  • Risk factors
  • Small lymphocytic lymphoma
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. / Kipps, Thomas J.; Fraser, Graeme; Coutre, Steven E.; Brown, Jennifer R.; Barrientos, Jacqueline C.; Barr, Paul M.; Byrd, John C.; O'Brien, Susan M.; Dilhuydy, Marie Sarah; Hillmen, Peter; Jaeger, Ulrich; Moreno, Carol; Cramer, Paula; Stilgenbauer, Stephan; Chanan-Khan, Asher A.; Mahler, Michelle; Salman, Mariya; Eckert, Karl; Solman, Isabelle G.; Balasubramanian, Sriram; Cheng, Mei; Londhe, Anil; Ninomoto, Joi; Howes, Angela; James, Danelle F.; Hallek, Michael.

In: Clinical Lymphoma, Myeloma and Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Kipps, TJ, Fraser, G, Coutre, SE, Brown, JR, Barrientos, JC, Barr, PM, Byrd, JC, O'Brien, SM, Dilhuydy, MS, Hillmen, P, Jaeger, U, Moreno, C, Cramer, P, Stilgenbauer, S, Chanan-Khan, AA, Mahler, M, Salman, M, Eckert, K, Solman, IG, Balasubramanian, S, Cheng, M, Londhe, A, Ninomoto, J, Howes, A, James, DF & Hallek, M 2019, 'Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia', Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2019.07.004
Kipps, Thomas J. ; Fraser, Graeme ; Coutre, Steven E. ; Brown, Jennifer R. ; Barrientos, Jacqueline C. ; Barr, Paul M. ; Byrd, John C. ; O'Brien, Susan M. ; Dilhuydy, Marie Sarah ; Hillmen, Peter ; Jaeger, Ulrich ; Moreno, Carol ; Cramer, Paula ; Stilgenbauer, Stephan ; Chanan-Khan, Asher A. ; Mahler, Michelle ; Salman, Mariya ; Eckert, Karl ; Solman, Isabelle G. ; Balasubramanian, Sriram ; Cheng, Mei ; Londhe, Anil ; Ninomoto, Joi ; Howes, Angela ; James, Danelle F. ; Hallek, Michael. / Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. In: Clinical Lymphoma, Myeloma and Leukemia. 2019.
@article{c5c07b7d9a7c470897d60d7813cb407b,
title = "Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia",
abstract = "A pooled analysis of 1238 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from three phase 3 studies found that genomic risk factors were not associated with shorter progression-free survival (PFS) or overall survival for patients treated with ibrutinib. Ibrutinib-treated patients with del(11q) were found to have a longer PFS than those without del(11q). These results suggest less prognostic relevance for certain genomic risk factors with ibrutinib treatment.",
keywords = "Prognostic factors, Risk factors, Small lymphocytic lymphoma, Survival",
author = "Kipps, {Thomas J.} and Graeme Fraser and Coutre, {Steven E.} and Brown, {Jennifer R.} and Barrientos, {Jacqueline C.} and Barr, {Paul M.} and Byrd, {John C.} and O'Brien, {Susan M.} and Dilhuydy, {Marie Sarah} and Peter Hillmen and Ulrich Jaeger and Carol Moreno and Paula Cramer and Stephan Stilgenbauer and Chanan-Khan, {Asher A.} and Michelle Mahler and Mariya Salman and Karl Eckert and Solman, {Isabelle G.} and Sriram Balasubramanian and Mei Cheng and Anil Londhe and Joi Ninomoto and Angela Howes and James, {Danelle F.} and Michael Hallek",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clml.2019.07.004",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

AU - Kipps, Thomas J.

AU - Fraser, Graeme

AU - Coutre, Steven E.

AU - Brown, Jennifer R.

AU - Barrientos, Jacqueline C.

AU - Barr, Paul M.

AU - Byrd, John C.

AU - O'Brien, Susan M.

AU - Dilhuydy, Marie Sarah

AU - Hillmen, Peter

AU - Jaeger, Ulrich

AU - Moreno, Carol

AU - Cramer, Paula

AU - Stilgenbauer, Stephan

AU - Chanan-Khan, Asher A.

AU - Mahler, Michelle

AU - Salman, Mariya

AU - Eckert, Karl

AU - Solman, Isabelle G.

AU - Balasubramanian, Sriram

AU - Cheng, Mei

AU - Londhe, Anil

AU - Ninomoto, Joi

AU - Howes, Angela

AU - James, Danelle F.

AU - Hallek, Michael

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A pooled analysis of 1238 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from three phase 3 studies found that genomic risk factors were not associated with shorter progression-free survival (PFS) or overall survival for patients treated with ibrutinib. Ibrutinib-treated patients with del(11q) were found to have a longer PFS than those without del(11q). These results suggest less prognostic relevance for certain genomic risk factors with ibrutinib treatment.

AB - A pooled analysis of 1238 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from three phase 3 studies found that genomic risk factors were not associated with shorter progression-free survival (PFS) or overall survival for patients treated with ibrutinib. Ibrutinib-treated patients with del(11q) were found to have a longer PFS than those without del(11q). These results suggest less prognostic relevance for certain genomic risk factors with ibrutinib treatment.

KW - Prognostic factors

KW - Risk factors

KW - Small lymphocytic lymphoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85071099545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071099545&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.07.004

DO - 10.1016/j.clml.2019.07.004

M3 - Article

AN - SCOPUS:85071099545

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -